OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")
Result of General Meeting
Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance testing, announces, further to the announcement of 19 June 2020, the passing of the Resolutions at the General Meeting held earlier today. The Placing, Subscription and Open Offer remain conditional on Admission of the New Ordinary Shares to AIM which is expected to take place at 8.00 a.m. Monday 13 July 2020.
Voting details
The vote for Resolution 1 was carried out as a poll on the basis of proxies received and the votes of those present (45,789,393 for and 167,575 against, with 54,677 votes withheld), and on the basis of such poll it was resolved that Resolution 1 as contained in the Notice be passed as an Ordinary Resolution.
The vote for Resolution 2 was carried out as a poll on the basis of proxies received and the votes of those present (45,789,393 for and 167,575 against, with 54,677 votes withheld), and on the basis of such poll it was resolved that Resolution 2 as contained in the Notice be passed as a Special Resolution.
Total Voting Rights
With effect from Admission the Company will have 178,153,110 Ordinary Shares in issue, with no shares held in treasury. Shareholders may use this figure as the denominator by which they are required to notify their interest in, or change to their interest in, the Company under the Disclosure Guidance and Transparency Rules.
Capitalised terms not otherwise defined in the text of this announcement have the meanings given to them in the Company's circular dated 19 June 2020.
For further information, please contact:
Omega Diagnostics Group PLC |
Tel: 01259 763 030 |
Colin King, Chief Executive |
|
Kieron Harbinson, Group Finance Director |
|
|
|
finnCap Ltd |
Tel: 020 7220 0500 |
Geoff Nash / Hannah Boros / Teddy Whiley (Corporate Finance) |
|
Camille Gochez (ECM) |
|
|
|
Walbrook PR Limited |
Tel: 020 7933 8780 or omega@walbrookpr.com |
Paul McManus |
Mob: 07980 541 893 |
Lianne Cawthorne |
Mob: 07584 391 303 |
Accordingly, the Company makes the following announcement and notification in accordance with the EU Market Abuse Regulation (No 596/2014):
1. |
Details of Persons Discharging Managerial Responsibilities "PDMR" / person closely associated with them ('PCA') |
|||||
a) |
Name |
Colin King |
||||
2. |
Reason for notification |
|||||
b) |
Position / status |
CEO |
||||
c) |
Initial notification / amendment |
Initial Notification |
||||
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
b) |
Name |
Omega Diagnostics Group plc |
||||
c) |
LEI |
2138007U9P4BTZTYIR92 |
||||
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
a) |
Description of the financial instrument
Identification code
|
ordinary shares of 4p each
GB00B1VCP282 |
||||
b) |
Nature of the transaction |
Acquisition of shares pursuant to the Placing |
||||
c) |
Price(s) and volume(s) |
|
||||
d) |
Aggregated information Aggregated volume Price |
n/a |
||||
e) |
Date of the transaction |
13 July 2020 |
||||
f) |
Place of the transaction |
London Stock Exchange, AIM Market (XLON) |
1. |
Details of Persons Discharging Managerial Responsibilities "PDMR" / person closely associated with them ('PCA') |
|||||
a) |
Name |
Kieron Harbinson |
||||
2. |
Reason for notification |
|||||
b) |
Position / status |
CFO |
||||
c) |
Initial notification / amendment |
Initial Notification |
||||
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
b) |
Name |
Omega Diagnostics Group plc |
||||
c) |
LEI |
2138007U9P4BTZTYIR92 |
||||
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
a) |
Description of the financial instrument
Identification code
|
ordinary shares of 4p each
GB00B1VCP282 |
||||
b) |
Nature of the transaction |
Acquisition of shares pursuant to the Subscription and Open Offer |
||||
c) |
Price(s) and volume(s) |
|
||||
d) |
Aggregated information Aggregated volume Price |
n/a |
||||
e) |
Date of the transaction |
13 July 2020 |
||||
f) |
Place of the transaction |
London Stock Exchange, AIM Market (XLON) |
1. |
Details of Persons Discharging Managerial Responsibilities "PDMR" / person closely associated with them ('PCA') |
|||||
a) |
Name |
Jag Grewal |
||||
2. |
Reason for notification |
|||||
b) |
Position / status |
Commercial Director |
||||
c) |
Initial notification / amendment |
Initial Notification |
||||
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
b) |
Name |
Omega Diagnostics Group plc |
||||
c) |
LEI |
2138007U9P4BTZTYIR92 |
||||
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
a) |
Description of the financial instrument
Identification code
|
ordinary shares of 4p each
GB00B1VCP282 |
||||
b) |
Nature of the transaction |
Acquisition of shares pursuant to the Placing |
||||
c) |
Price(s) and volume(s) |
|
||||
d) |
Aggregated information Aggregated volume Price |
n/a |
||||
e) |
Date of the transaction |
13 July 2020 |
||||
f) |
Place of the transaction |
London Stock Exchange, AIM Market (XLON) |
1. |
Details of Persons Discharging Managerial Responsibilities "PDMR" / person closely associated with them ('PCA') |
|||||
a) |
Name |
Jeremy Millard |
||||
2. |
Reason for notification |
|||||
b) |
Position / status |
Non-Executive Director |
||||
c) |
Initial notification / amendment |
Initial Notification |
||||
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
b) |
Name |
Omega Diagnostics Group plc |
||||
c) |
LEI |
2138007U9P4BTZTYIR92 |
||||
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
a) |
Description of the financial instrument
Identification code
|
ordinary shares of 4p each
GB00B1VCP282 |
||||
b) |
Nature of the transaction |
Acquisition of shares pursuant to the Subscription |
||||
c) |
Price(s) and volume(s) |
|
||||
d) |
Aggregated information Aggregated volume Price |
n/a |
||||
e) |
Date of the transaction |
13 July 2020 |
||||
f) |
Place of the transaction |
London Stock Exchange, AIM Market (XLON) |